Compare MLAB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | FDMT |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 391.8M |
| IPO Year | N/A | 2020 |
| Metric | MLAB | FDMT |
|---|---|---|
| Price | $80.40 | $7.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $83.00 | $30.33 |
| AVG Volume (30 Days) | 104.9K | ★ 1.2M |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,255,000.00 | $120,000.00 |
| Revenue This Year | $4.96 | $21,181.08 |
| Revenue Next Year | $5.27 | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.39 | ★ 605.88 |
| 52 Week Low | $55.45 | $2.24 |
| 52 Week High | $155.12 | $12.34 |
| Indicator | MLAB | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 33.92 |
| Support Level | $76.52 | $7.67 |
| Resistance Level | $82.78 | $11.81 |
| Average True Range (ATR) | 2.57 | 0.80 |
| MACD | 0.11 | -0.32 |
| Stochastic Oscillator | 73.53 | 5.72 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.